Drug profile · INN
ipratropium bromide
IPRATROPIUM BROMIDE
ipratropium bromide (IPRATROPIUM BROMIDE) is a muscarinic acetylcholine receptor m3 antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: inhalation. Current US regulatory status: approved.
Drug details — ipratropium bromide
- US status
- approved
- Class
- —
- Route
- INHALATION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
ipratropium bromide (IPRATROPIUM BROMIDE) is a muscarinic acetylcholine receptor m3 antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: inhalation. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscarinic acetylcholine receptor M3 antagonist
Primary target: Muscarinic acetylcholine receptor M3
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is ipratropium bromide?
ipratropium bromide (IPRATROPIUM BROMIDE) is a muscarinic acetylcholine receptor m3 antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: inhalation. Current US regulatory status: approved.
What is the brand name for ipratropium bromide?
IPRATROPIUM BROMIDE is a marketed brand name for ipratropium bromide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ipratropium bromide?
ipratropium bromide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.